DSM-265

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H12F7N5S
Molecular Weight	415.332
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=NC(=NN2C(NC3=CC=C(C=C3)S(F)(F)(F)(F)F)=C1)C(C)(F)F

InChI

InChIKey=OIZSVTOIBNSVOS-UHFFFAOYSA-N

InChI=1S/C14H12F7N5S/c1-8-7-11(26-13(22-8)24-12(25-26)14(2,15)16)23-9-3-5-10(6-4-9)27(17,18,19,20)21/h3-7,23H,1-2H3

HIDE SMILES / InChI

Molecular Formula	C14H12F7N5S
Molecular Weight	415.332
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28363637 | https://adisinsight.springer.com/drugs/800039314 | https://newdrugapprovals.org/2016/05/23/dsm-265-a-promising-antimalarial/

DSM265 is an experimental antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase (DHODH). DSM265 is the first DHODH inhibitor to reach clinical development for treatment of malaria. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drug-resistant parasite isolates. The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dihydroorotate dehydrogenase 10 Target ID: CHEMBL3486 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21696174	Inhibitor 8504

PubMed

Title	Date	PubMed
DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum.	2019-04	30858218
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.	2019-01-11	30375858
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria.	2018-08	29909070
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.	2018-08	29909069
A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation.	2018-02-14	29216395
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.	2017-06	28363637
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.	2017-06	28363636
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.	2015-07-15	26180101
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.	2011-08-11	21696174

Patents

Sample Use Guides

In Vivo Use Guide

Single dose of 400 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:54:23 GMT 2025` Edited by `admin` on `Tue Apr 01 16:54:23 GMT 2025`
Record UNII	0Q42P4YI6B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DSM-265

Common Name

English

DSM265

Preferred Name

English

2-(1,1-DIFLUOROETHYL)-5-METHYL-N-(4-(PENTAFLUORO-.LAMBDA.6-SULFANYL)PHENYL) (1,2,4)TRIAZOLO(1,5-A)PYRIMIDIN-7-AMINE

Systematic Name

English

SULFUR, (4-((2-(1,1-DIFLUOROETHYL)-5-METHYL(1,2,4)TRIAZOLO(1,5-A)PYRIMIDIN-7-YL)AMINO)PHENYL)PENTAFLUORO-, (OC-6-21)-

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

598417